Iloprost Therapy in Patients With Critical Limb Ischemia: Evaluation of Efficacy and Safety
Phase of Trial: Phase IV
Latest Information Update: 05 Mar 2015
At a glance
- Drugs Iloprost (Primary)
- Indications Embolism and thrombosis; Peripheral arterial disorders; Peripheral ischaemia
- Focus Therapeutic Use
- Sponsors Bayer
- 01 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Dec 2014 Planned End Date changed from 1 Sep 2014 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
- 05 Sep 2014 Planned End Date changed from 1 Jul 2014 to 1 Sep 2014, as reported by the ClinicalTrials.gov record.